Clinical Trial Update: LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update covers a Phase 1/2 study evaluating LY3214996 with cetuximab, alone or in combination with abemaciclib, for unresectable or metastati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer
• Rectal Cancer
• Unresectable Colon Cancer
• Unresectable Colorectal Cancer
• Unresectable Rectal Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)
• Cetuximab (cetuximab)
• LY3214996

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING